Torsades de Pointes Following Massive Transfusion Protocol: Case Highlighting Electrolyte Disturbances After Blood Product Administration
- PMID: 40883076
- PMCID: PMC12402345
- DOI: 10.1016/j.jaccas.2025.104795
Torsades de Pointes Following Massive Transfusion Protocol: Case Highlighting Electrolyte Disturbances After Blood Product Administration
Abstract
Background: Torsades de Pointes (TdP) is caused by QT-prolonging medications, electrolyte disturbances, structural heart disease, congenital long-QT syndromes, female gender, and age. If left untreated, it can lead to cardiac arrest and death.
Case summary: In this report, we highlight a case of TdP after the transfusion of massive blood products leading to electrolyte disturbances causing QT prolongation.
Discussion: This case underscores the need for careful electrolyte monitoring and QT assessment in patients receiving large-volume blood products, and refinement of guidelines regarding electrolyte monitoring and repletion posttransfusion.
Take-home messages: TdP is an often-fatal arrhythmia that can be caused by QT prolongation secondary to electrolyte disturbances. Massive blood transfusions can predispose patients to electrolyte depletion, QT prolongation, and TdP. Further refinement of guidelines regarding electrolyte monitoring and QT interval assessment is warranted to prevent complications such as TdP.
Keywords: QT prolongation; Torsades de Pointes; hypocalcemia; hypokalemia; hypomagnesemia; hypophosphatemia; massive transfusion protocol; ventricular arrhythmias.
Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Figures




Similar articles
-
Torsade de Pointes and QT Prolongation Among Antifungal Triazoles: A Real-World, Retrospective, Observational, Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database.Cardiovasc Toxicol. 2025 Oct;25(10):1616-1633. doi: 10.1007/s12012-025-10051-1. Epub 2025 Aug 6. Cardiovasc Toxicol. 2025. PMID: 40768016
-
Validation of a Clinical Decision Support Tool for Quantifying Risk of Torsades de Pointes in a Psychiatric Inpatient Population.Innov Clin Neurosci. 2025 Jun 1;22(4-6):14-19. eCollection 2025 Apr-Jun. Innov Clin Neurosci. 2025. PMID: 40786905 Free PMC article.
-
Mechanisms underlying the spontaneous termination of torsades de pointes in an experimental model of long QT syndrome.Heart Rhythm. 2025 Aug;22(8):2092-2098. doi: 10.1016/j.hrthm.2024.10.009. Epub 2024 Oct 9. Heart Rhythm. 2025. PMID: 39389521
-
Prevalence of QT-Prolonging Drug-Drug Interactions in Psychiatry: A Systematic Review and Meta Analysis.J Pharm Pract. 2024 Feb;37(1):162-168. doi: 10.1177/08971900221121371. Epub 2022 Aug 14. J Pharm Pract. 2024. PMID: 35968552
-
Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports.Psychopharmacology (Berl). 2013 Aug;228(4):515-24. doi: 10.1007/s00213-013-3192-8. Epub 2013 Jun 30. Psychopharmacology (Berl). 2013. PMID: 23812796
References
-
- Hubbard W.J., Meador S.A., Kerby J.D., et al. The role of calcium in blood coagulation: effects of hypocalcemia on coagulation tests. Anaesthesia. 1992;47(5):389–392. doi: 10.1111/j.1365-2044.1992.tb02008.x. - DOI
-
- Hunt B. StatPearls. StatPearls Publishing; 2024. Biochemistry, clotting factors.
-
- Sandler S.G., Mallory D., Malamut D., Eckman M.H. Massive transfusion and the role of calcium. Transfusion. 2019;59(S2):1459–1465. doi: 10.1111/trf.15241. - DOI
Publication types
LinkOut - more resources
Full Text Sources